NET-ting the autoreactive B cell memory by therapeutically targeting the humoral autoimmunity in patients with SLE

Objectives of the Project

Patients with SLE typically have circulating autoantibodies against DNA as a result of a humoral (auto-)immune response. The research project intends to  comprehensively study the pathophysiology of the humoral autoimmune response in SLE patients. To do so, we intend to establish an in-depth understanding of the origins of SLE-specifi c autoantibodies in a unique
cohort of SLE patients who are treated with new biological therapies specifi cally targeted
at the formation of autoantibodies.

Facts and Figures

Project Lead
Dr. Y. K. O. Teng
University Medical Center Leiden
FOREUM research grant: € 300.000
April 2016, Duration 3 years

Meet the Team

Dr. Y. K. O. Teng
University Medical Center Leiden
Prof. R. Voll
Albert Ludwig University Freiburg
Prof. D. Isenberg
University College London

Patient Voice

The experimental nature of our research proposal limits the potential contribution of patient research partners. It is however noteworthy that patient representatives are involved in the separate clinical trials at each collaborating centre which investigate therapeutic strategies that specifically target humoral autoimmunity.

Publications

EULAR 2017 ABSTRACTS

OP0302 - significant reductions of pathogenic autoantibodies by synergetic rituximab and belimumab treatment effectively inhibits neutrophil extracellular traps in severe, refractory sle - the synbiose study

SAT0258 - synergetic b-cell immunomodulation with rituximab and belimumab is clinically effective in severe and refractory systemic lupus erythematosus - the synbiose proof-of-concept study